MedTrace Logo

AZD5069 Neutrophil Function Study

NCT01480739 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-06-25

No results posted yet for this study

Summary

Study in healthy volunteer to see effect of AZD5069 and placebo on neutrophil number and function (phagocytosis and oxidative burst) in the circulation, following a burst of strenuous exercise and following subcutaneous injection of granulocyte-colony stimulating factor (G-CSF)

Conditions

  • Chemokine Receptor 2 (CXCR2) Antagonist

Interventions

DRUG

100 mg (50 mg x 2) AZD5069

Twice daily for 7 days

DRUG

100 mg Placebo

Twice daily for 7 days

Sponsors & Collaborators

Principal Investigators

  • Tim Mant, MD · Quintiles research Unit

  • Bengt Larsson, MD · AstraZeneca Medical Science Director

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01480739 on ClinicalTrials.gov